Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development (Q37330751)

19 August 2017

1 reference

title

Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development (English)

1 reference

19 August 2017

0 references

3

Alan Barrett

1 reference

19 August 2017

2

Joachim Hombach

1 reference

19 August 2017

Stephen J Thomas

1

1 reference

PubMed ID

19022321

19 August 2017

language of work or name

English

0 references

publication date

18 November 2008

1 reference

19 August 2017

1 reference

19 August 2017

27

1 reference

19 August 2017

3

1 reference

19 August 2017

355-368

1 reference

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Immunology and immunopathogenesis of dengue disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

A dominant role for FcgammaRII in antibody-enhanced dengue virus infection of human mast cells and associated CCL5 release.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Differential Enhancement of Dengue Virus Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human Fc RIA (CD64) or Fc RIIA (CD32)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Influence of the human high-affinity IgG receptor FcgammaRI (CD64) on residual infectivity of neutralized dengue virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Immunopathological mechanisms in dengue and dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dengue: defining protective versus pathologic immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Immunopathogenesis of Dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dengue and yellow fever--challenges for the development and use of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Decline in Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity with Increasing Age and Boosting with a High‐Dose VZV Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Clinical responses to undiluted and diluted smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Monitoring HIV-specific CD8+ T cell responses by intracellular cytokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Potential underestimation of HLA-C-restricted cytotoxic T-lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

HIV evolution: CTL escape mutation and reversion after transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

HLA and AIDS: a cautionary tale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

The Role of CD4(+) and CD8(+) T Cells in Controlling HIV Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Skewed maturation of memory HIV-specific CD8 T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Viral evolution and challenges in the development of HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dengue in the Americas and Southeast Asia: do they differ?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Primary and Secondary Infections of Macaca fascicularis Monkeys with Asian and American Genotypes of Dengue Virus 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dengue and dengue haemorrhagic fever: implications of host genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

A variant in the CD209 promoter is associated with severity of dengue disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Phylogenetic relationships and differential selection pressures among genotypes of dengue-2 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Phylogenetic evidence for adaptive evolution of dengue viruses in nature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Selection for virulent dengue viruses occurs in humans and mosquitoes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Inhibition of interferon signaling by dengue virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

No one is naive: the significance of heterologous T-cell immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Selective induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Immunopathogenesis of vaccine-enhanced RSV disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

HLA-A, -B, -DRB1, -DQA1, and -DQB1 polymorphism in Thais

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Human dendritic cells as targets of dengue virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dengue virus and dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Comparison by flow cytometry of immune changes induced in human monocyte-derived dendritic cells upon infection with dengue 2 live-attenuated vaccine or 16681 parental strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Cross-Reactive T-Cell Responses to the Nonstructural Regions of Dengue Viruses among Dengue Fever and Dengue Hemorrhagic Fever Patients in Malaysia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

"Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

inferred from DOI database lookup

7 January 2021

based on heuristic

Original antigenic sin in dengue

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

inferred from DOI database lookup

7 January 2021

based on heuristic

Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.086

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.10.086

1 reference

19 August 2017

1 reference

PubMed ID

19022321